메뉴 건너뛰기




Volumn 9, Issue 3, 2009, Pages 166-172

A phase II trial of a neoadjuvant platinum regimen for locally advanced breast cancer: pathologic response, long-term follow-up, and correlation with biomarkers

Author keywords

Cisplatin; Doxorubicin; P53; Paclitaxel; Topoisomerase II

Indexed keywords

BIOLOGICAL MARKER; CIPROFLOXACIN; CISPLATIN; COTRIMOXAZOLE; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL; PLATINUM; PROTEIN P53; TAMOXIFEN; ANTINEOPLASTIC AGENT; DNA BINDING PROTEIN; DNA TOPOISOMERASE II ALPHA; TUMOR ANTIGEN; TUMOR MARKER;

EID: 70350765062     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2009.n.027     Document Type: Article
Times cited : (15)

References (46)
  • 1
    • 39149103122 scopus 로고    scopus 로고
    • Locally advanced and inflammatory breast cancer
    • Chia S, Swain SM, Byrd DR, et al. Locally advanced and inflammatory breast cancer. J Clin Oncol 2008;26:786-90.
    • (2008) J Clin Oncol , vol.26 , pp. 786-790
    • Chia, S.1    Swain, S.M.2    Byrd, D.R.3
  • 2
    • 36448985969 scopus 로고    scopus 로고
    • Preoperative chemotherapy treatment of breast cancer-a review
    • Buzdar AU. Preoperative chemotherapy treatment of breast cancer-a review. Cancer 2007;110:2394-407.
    • (2007) Cancer , vol.110 , pp. 2394-2407
    • Buzdar, A.U.1
  • 3
    • 0035751675 scopus 로고    scopus 로고
    • Preoperative chemotherapy in patients with operable breast cancer: Nine-year results from national surgical adjuvant breast and bowel project B-18
    • Wolmark N, Wang J, Mamounas E, et al. Preoperative chemotherapy in patients with operable breast cancer: Nine-year results from national surgical adjuvant breast and bowel project B-18. J Natl Cancer Inst Monogr 2001;30:96-102.
    • (2001) J Natl Cancer Inst Monogr , vol.30 , pp. 96-102
    • Wolmark, N.1    Wang, J.2    Mamounas, E.3
  • 4
    • 16644384267 scopus 로고    scopus 로고
    • Randomized parallel study of doxorubicin plus paclitaxel and doxorubicin plus cyclophosphamide as neoadjuvant treatment of patients with breast cancer
    • Dieras V, Fumoleau P, Romieu G, et al. Randomized parallel study of doxorubicin plus paclitaxel and doxorubicin plus cyclophosphamide as neoadjuvant treatment of patients with breast cancer. J Clin Oncol 2004;22:4958-65.
    • (2004) J Clin Oncol , vol.22 , pp. 4958-4965
    • Dieras, V.1    Fumoleau, P.2    Romieu, G.3
  • 5
    • 33646445341 scopus 로고    scopus 로고
    • Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National surgical adjuvant breast and bowel project protocol B-27
    • Bear HD, Anderson S, Smith RE, et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National surgical adjuvant breast and bowel project protocol B-27. J Clin Oncol 2006;24:2019-27.
    • (2006) J Clin Oncol , vol.24 , pp. 2019-2027
    • Bear, H.D.1    Anderson, S.2    Smith, R.E.3
  • 6
    • 2642585065 scopus 로고    scopus 로고
    • A novel continuous infusional 5-fluorouracil-based chemotherapy regimen compared with conventional chemotherapy in the neo-adjuvant treatment of early breast cancer: 5 year results of the TOPIC trial
    • Smith IE, A'Hern R P, Coombes GA, et al. A novel continuous infusional 5-fluorouracil-based chemotherapy regimen compared with conventional chemotherapy in the neo-adjuvant treatment of early breast cancer: 5 year results of the TOPIC trial. Ann Oncol 2004;15:751-8.
    • (2004) Ann Oncol , vol.15 , pp. 751-758
    • Smith, I.E.1    A'Hern, R.P.2    Coombes, G.A.3
  • 7
    • 34247262143 scopus 로고    scopus 로고
    • A phase II study of epirubicin, cisplatin and capecitabine as neoadjuvant chemotherapy in locally advanced or inflammatory breast cancer
    • Villman K, Ohd J F, Lidbrink E, et al. A phase II study of epirubicin, cisplatin and capecitabine as neoadjuvant chemotherapy in locally advanced or inflammatory breast cancer. Eur J Cancer 2007;43:1153-60.
    • (2007) Eur J Cancer , vol.43 , pp. 1153-1160
    • Villman, K.1    Ohd, J.F.2    Lidbrink, E.3
  • 8
    • 12144281589 scopus 로고    scopus 로고
    • Docetaxel and cisplatin as primary chemotherapy for treatment of locally advanced breast cancers
    • Lee YJ, Doliny P, Gomez-Fernandez C, et al. Docetaxel and cisplatin as primary chemotherapy for treatment of locally advanced breast cancers. Clin Breast Cancer 2004;5:371-6.
    • (2004) Clin Breast Cancer , vol.5 , pp. 371-376
    • Lee, Y.J.1    Doliny, P.2    Gomez-Fernandez, C.3
  • 9
    • 34447545884 scopus 로고    scopus 로고
    • Multicenter phase II trial of neoadjuvant therapy with trastuzumab, docetaxel, and carboplatin for human epidermal growth factor receptor-2-overexpressing stage II or III breast cancer: Results of the GETN (A)-1 trial
    • Coudert B P, Largillier R, Arnould L, et al. Multicenter phase II trial of neoadjuvant therapy with trastuzumab, docetaxel, and carboplatin for human epidermal growth factor receptor-2-overexpressing stage II or III breast cancer: Results of the GETN (A)-1 trial. J Clin Oncol 2007;25:2678-84.
    • (2007) J Clin Oncol , vol.25 , pp. 2678-2684
    • Coudert, B.P.1    Largillier, R.2    Arnould, L.3
  • 10
    • 47549084272 scopus 로고    scopus 로고
    • Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel
    • Torrisi R, Balduzzi A, Ghisini R, et al. Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel. Cancer Chemother Pharmacol; 2008;62:667-72.
    • (2008) Cancer Chemother Pharmacol , vol.62 , pp. 667-672
    • Torrisi, R.1    Balduzzi, A.2    Ghisini, R.3
  • 11
    • 54949097426 scopus 로고    scopus 로고
    • Platinum-based chemotherapy in triple-negative breast cancer
    • Sirohi B, Arnedos M, Popat S, et al. Platinum-based chemotherapy in triple-negative breast cancer. Ann Oncol 2008;19:1847-52.
    • (2008) Ann Oncol , vol.19 , pp. 1847-1852
    • Sirohi, B.1    Arnedos, M.2    Popat, S.3
  • 12
    • 9244223030 scopus 로고    scopus 로고
    • Phase I/II trial of biweekly paclitaxel and cisplatin in the treatment of metastatic breast cancer
    • Gelmon KA, O'Reilly SE, Tolcher AW, et al. Phase I/II trial of biweekly paclitaxel and cisplatin in the treatment of metastatic breast cancer. J Clin Oncol 1996;14:1185-91.
    • (1996) J Clin Oncol , vol.14 , pp. 1185-1191
    • Gelmon, K.A.1    O'Reilly, S.E.2    Tolcher, A.W.3
  • 13
    • 0028877036 scopus 로고
    • Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: High antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study
    • Gianni L, Munzone E, Capri G, et al. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: High antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 1995;13:2688-99.
    • (1995) J Clin Oncol , vol.13 , pp. 2688-2699
    • Gianni, L.1    Munzone, E.2    Capri, G.3
  • 14
    • 0033050164 scopus 로고    scopus 로고
    • Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy
    • Kuerer HM, Newman LA, Smith TL, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 1999;17:460-9.
    • (1999) J Clin Oncol , vol.17 , pp. 460-469
    • Kuerer, H.M.1    Newman, L.A.2    Smith, T.L.3
  • 15
    • 0031926839 scopus 로고    scopus 로고
    • Effect of preoperative chemotherapy on the outcome of women with operable breast cancer
    • Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998;16:2672-85.
    • (1998) J Clin Oncol , vol.16 , pp. 2672-2685
    • Fisher, B.1    Bryant, J.2    Wolmark, N.3
  • 16
    • 33847063053 scopus 로고    scopus 로고
    • The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes
    • Carey LA, Dees EC, Sawyer L, et al. The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007;13:2329-34.
    • (2007) Clin Cancer Res , vol.13 , pp. 2329-2334
    • Carey, L.A.1    Dees, E.C.2    Sawyer, L.3
  • 17
    • 23844549918 scopus 로고    scopus 로고
    • Breast cancer molecular subtypes respond differently to preoperative chemotherapy
    • Rouzier R, Perou CM, Symmans W F, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005;11:5678-85.
    • (2005) Clin Cancer Res , vol.11 , pp. 5678-5685
    • Rouzier, R.1    Perou, C.M.2    Symmans, W.F.3
  • 18
    • 0023006005 scopus 로고
    • Isolation and expression of a complementary DNA that confers multidrug resistance
    • Gros P, Ben Neriah YB, Croop JM, et al. Isolation and expression of a complementary DNA that confers multidrug resistance. Nature 1986;323:728-31.
    • (1986) Nature , vol.323 , pp. 728-731
    • Gros, P.1    Ben Neriah, Y.B.2    Croop, J.M.3
  • 19
    • 0031160951 scopus 로고    scopus 로고
    • Structure of the multidrug resistance P-glycoprotein
    • Higgins C F, Callaghan R, Linton KJ, et al. Structure of the multidrug resistance P-glycoprotein. Semin Cancer Biol 1997;8:135-42.
    • (1997) Semin Cancer Biol , vol.8 , pp. 135-142
    • Higgins, C.F.1    Callaghan, R.2    Linton, K.J.3
  • 20
    • 0029954845 scopus 로고    scopus 로고
    • Biology of the multidrug resistance-associated protein, MRP
    • Loe DW, Deeley RG, Cole S P. Biology of the multidrug resistance-associated protein, MRP. Eur J Cancer 1996;32A:945-57.
    • (1996) Eur J Cancer , vol.32 A , pp. 945-957
    • Loe, D.W.1    Deeley, R.G.2    Cole, S.P.3
  • 21
    • 0036364467 scopus 로고    scopus 로고
    • Multidrug resistance in cancer: Role of ATP-dependent transporters
    • Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: Role of ATP-dependent transporters. Nat Rev Cancer 2002;2:48-58.
    • (2002) Nat Rev Cancer , vol.2 , pp. 48-58
    • Gottesman, M.M.1    Fojo, T.2    Bates, S.E.3
  • 22
    • 0030920342 scopus 로고    scopus 로고
    • Multidrug resistance in breast cancer: A metaanalysis of MDR1/gp170 expression and its possible functional significance
    • Trock BJ, Leonessa F, Clarke R. Multidrug resistance in breast cancer: A metaanalysis of MDR1/gp170 expression and its possible functional significance. J Natl Cancer Inst 1997;89:917-31.
    • (1997) J Natl Cancer Inst , vol.89 , pp. 917-931
    • Trock, B.J.1    Leonessa, F.2    Clarke, R.3
  • 23
    • 0034667390 scopus 로고    scopus 로고
    • Extensive contribution of the multidrug transporters P-glycoprotein and Mrp1 to basal drug resistance
    • Allen JD, Brinkhuis R F, van Deemter L, et al. Extensive contribution of the multidrug transporters P-glycoprotein and Mrp1 to basal drug resistance. Cancer Res 2000;60:5761-6.
    • (2000) Cancer Res , vol.60 , pp. 5761-5766
    • Allen, J.D.1    Brinkhuis, R.F.2    van Deemter, L.3
  • 24
    • 0036569471 scopus 로고    scopus 로고
    • Assessment of molecular markers of clinical sensitivity to single-agent taxane therapy for metastatic breast cancer
    • Van Poznak C, Tan L, Panageas KS, et al. Assessment of molecular markers of clinical sensitivity to single-agent taxane therapy for metastatic breast cancer. J Clin Oncol 2002;20:2319-26.
    • (2002) J Clin Oncol , vol.20 , pp. 2319-2326
    • Van Poznak, C.1    Tan, L.2    Panageas, K.S.3
  • 25
    • 4544357777 scopus 로고    scopus 로고
    • Investigation of MRP-1 protein and MDR-1 P-glycoprotein expression in invasive breast cancer: A prognostic study
    • Larkin A, O'Driscoll L, Kennedy S, et al. Investigation of MRP-1 protein and MDR-1 P-glycoprotein expression in invasive breast cancer: A prognostic study. Int J Cancer 2004;112:286-94.
    • (2004) Int J Cancer , vol.112 , pp. 286-294
    • Larkin, A.1    O'Driscoll, L.2    Kennedy, S.3
  • 26
    • 33344456074 scopus 로고    scopus 로고
    • Prognostic impact of multidrug resistance gene expression on the management of breast cancer in the context of adjuvant therapy based on a series of 171 patients
    • Moureau-Zabotto L, Ricci S, Lefranc J P, et al. Prognostic impact of multidrug resistance gene expression on the management of breast cancer in the context of adjuvant therapy based on a series of 171 patients. Br J Cancer 2006;94:473-80.
    • (2006) Br J Cancer , vol.94 , pp. 473-480
    • Moureau-Zabotto, L.1    Ricci, S.2    Lefranc, J.P.3
  • 27
    • 0026630604 scopus 로고
    • P53 mutations in breast cancer
    • Coles C, Condie A, Chetty U, et al. P53 mutations in breast cancer. Cancer Res 1992;52:5291-8.
    • (1992) Cancer Res , vol.52 , pp. 5291-5298
    • Coles, C.1    Condie, A.2    Chetty, U.3
  • 28
    • 0030865104 scopus 로고    scopus 로고
    • Characterization of the p53 tumor suppressor pathway in cell lines of the national cancer institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents
    • O'Connor PM, Jackman J, Bae I, et al. Characterization of the p53 tumor suppressor pathway in cell lines of the national cancer institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res 1997;57:4285-300.
    • (1997) Cancer Res , vol.57 , pp. 4285-4300
    • O'Connor, P.M.1    Jackman, J.2    Bae, I.3
  • 29
    • 17744403009 scopus 로고    scopus 로고
    • Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer
    • Berns EM, Foekens JA, Vossen R, et al. Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer. Cancer Res 2000;60:2155-62.
    • (2000) Cancer Res , vol.60 , pp. 2155-2162
    • Berns, E.M.1    Foekens, J.A.2    Vossen, R.3
  • 30
    • 12244252332 scopus 로고    scopus 로고
    • Predictive value of tumour cell proliferation in locally advanced breast cancer treated with neoadjuvant chemotherapy
    • Aas T, Geisler S, Eide GE, et al. Predictive value of tumour cell proliferation in locally advanced breast cancer treated with neoadjuvant chemotherapy. Eur J Cancer 2003;39:438-46.
    • (2003) Eur J Cancer , vol.39 , pp. 438-446
    • Aas, T.1    Geisler, S.2    Eide, G.E.3
  • 31
    • 0035866772 scopus 로고    scopus 로고
    • Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer
    • Geisler S, Lonning PE, Aas T, et al. Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Res 2001;61:2505-12.
    • (2001) Cancer Res , vol.61 , pp. 2505-2512
    • Geisler, S.1    Lonning, P.E.2    Aas, T.3
  • 32
    • 0141614011 scopus 로고    scopus 로고
    • Topoisomerase II alpha as a marker predicting the efficacy of anthracyclines in breast cancer: Are we at the end of the beginning?
    • Di Leo A, Isola J. Topoisomerase II alpha as a marker predicting the efficacy of anthracyclines in breast cancer: Are we at the end of the beginning? Clin Breast Cancer 2003;4:179-86.
    • (2003) Clin Breast Cancer , vol.4 , pp. 179-186
    • Di Leo, A.1    Isola, J.2
  • 33
    • 45149122291 scopus 로고    scopus 로고
    • The value of TOP2A gene copy number variation as a biomarker in breast cancer: Update of DBCG trial 89D
    • Nielsen KV, Ejlertsen B, Moller S, et al. The value of TOP2A gene copy number variation as a biomarker in breast cancer: Update of DBCG trial 89D. Acta Oncol 2008;47:725-34.
    • (2008) Acta Oncol , vol.47 , pp. 725-734
    • Nielsen, K.V.1    Ejlertsen, B.2    Moller, S.3
  • 34
    • 84898697559 scopus 로고    scopus 로고
    • NCIC. National cancer institute of canada: Common toxicity criteria (CTC). 2nd ed. NCIC CTG pocket book; 1998.
    • NCIC. National cancer institute of canada: Common toxicity criteria (CTC). 2nd ed. NCIC CTG pocket book; 1998.
  • 35
    • 0019365237 scopus 로고
    • Reporting results of cancer treatment
    • Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer 1981;47:207-14.
    • (1981) Cancer , vol.47 , pp. 207-214
    • Miller, A.B.1    Hoogstraten, B.2    Staquet, M.3
  • 36
    • 7044272570 scopus 로고    scopus 로고
    • Long-term follow-up for locally advanced and inflammatory breast cancer patients treated with multimodality therapy
    • Low JA, Berman AW, Steinberg SM, et al. Long-term follow-up for locally advanced and inflammatory breast cancer patients treated with multimodality therapy. J Clin Oncol 2004;22:4067-74.
    • (2004) J Clin Oncol , vol.22 , pp. 4067-4074
    • Low, J.A.1    Berman, A.W.2    Steinberg, S.M.3
  • 37
    • 17444454498 scopus 로고    scopus 로고
    • Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: Findings from national surgical adjuvant breast and bowel project B-18
    • Fisher B, Brown A, Mamounas E, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: Findings from national surgical adjuvant breast and bowel project B-18. J Clin Oncol 1997;15:2483-93.
    • (1997) J Clin Oncol , vol.15 , pp. 2483-2493
    • Fisher, B.1    Brown, A.2    Mamounas, E.3
  • 38
    • 0037365648 scopus 로고    scopus 로고
    • Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer: An EORTC-NCIC-SAKK multicenter study
    • Therasse P, Mauriac L, Welnicka-Jaskiewicz M, et al. Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer: An EORTC-NCIC-SAKK multicenter study. J Clin Oncol 2003;21:843-50.
    • (2003) J Clin Oncol , vol.21 , pp. 843-850
    • Therasse, P.1    Mauriac, L.2    Welnicka-Jaskiewicz, M.3
  • 39
    • 58049208408 scopus 로고    scopus 로고
    • Assessment of different criteria for the pathological complete response (pCR) to primary chemotherapy in breast cancer: Standardization is needed
    • Mukai H, Watanabe T, Ando M, et al. Assessment of different criteria for the pathological complete response (pCR) to primary chemotherapy in breast cancer: Standardization is needed. Breast Cancer Res Treat 2009;113:123-8.
    • (2009) Breast Cancer Res Treat , vol.113 , pp. 123-128
    • Mukai, H.1    Watanabe, T.2    Ando, M.3
  • 40
    • 39149111633 scopus 로고    scopus 로고
    • Preoperative chemotherapy: Updates of national surgical adjuvant breast and bowel project protocols B-18 and B-27
    • Rastogi P, Anderson SJ, Bear HD, et al. Preoperative chemotherapy: Updates of national surgical adjuvant breast and bowel project protocols B-18 and B-27. J Clin Oncol 2008;26:778-85.
    • (2008) J Clin Oncol , vol.26 , pp. 778-785
    • Rastogi, P.1    Anderson, S.J.2    Bear, H.D.3
  • 41
    • 0030805625 scopus 로고    scopus 로고
    • NSABP protocol B-27. preoperative doxorubicin plus cyclophosphamide followed by preoperative or postoperative docetaxel
    • Mamounas E P. NSABP protocol B-27. preoperative doxorubicin plus cyclophosphamide followed by preoperative or postoperative docetaxel. Oncology Williston Park 1997;11(suppl 6):37-40.
    • (1997) Oncology Williston Park , vol.11 , Issue.SUPPL. 6 , pp. 37-40
    • Mamounas, E.P.1
  • 42
    • 33846297680 scopus 로고    scopus 로고
    • Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: An update of the initial randomized study population and data of additional patients treated with the same regimen
    • Buzdar AU, Valero V, Ibrahim NK, et al. Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: An update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res 2007;13:228-33.
    • (2007) Clin Cancer Res , vol.13 , pp. 228-233
    • Buzdar, A.U.1    Valero, V.2    Ibrahim, N.K.3
  • 43
    • 70249123201 scopus 로고    scopus 로고
    • Neoadjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer: Primary efficacy analysis of the NOAH trial
    • Presented at: December 10-14, San Antonio, TX. Abstract 31
    • Gianni L, Eiermann W, Semiglazov, et al. Neoadjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer: primary efficacy analysis of the NOAH trial. Presented at: the 31st Annual San Antonio Breast Cancer Symposiun; December 10-14, 2008; San Antonio, TX. Abstract 31.
    • (2008) the 31st Annual San Antonio Breast Cancer Symposiun
    • Gianni, L.1    Eiermann, W.2    Semiglazov3
  • 44
    • 38349084668 scopus 로고    scopus 로고
    • Does estrogen receptor negative/progesterone receptor positive breast carcinoma exist?
    • author reply 336-8
    • De Maeyer L, Van Limbergen E, De Nys K, et al. Does estrogen receptor negative/progesterone receptor positive breast carcinoma exist? J Clin Oncol 2008;26:335; author reply 336-8.
    • (2008) J Clin Oncol , vol.26 , pp. 335
    • De Maeyer, L.1    Van Limbergen, E.2    De Nys, K.3
  • 45
    • 25144504517 scopus 로고    scopus 로고
    • Expression of mucins (MUC1, MUC2, MUC3, MUC4, MUC5AC and MUC6) and their prognostic significance in human breast cancer
    • Rakha EA, Boyce RW, Abd El-Rehim D, et al. Expression of mucins (MUC1, MUC2, MUC3, MUC4, MUC5AC and MUC6) and their prognostic significance in human breast cancer. Mod Pathol 2005;18:1295-304.
    • (2005) Mod Pathol , vol.18 , pp. 1295-1304
    • Rakha, E.A.1    Boyce, R.W.2    Abd El-Rehim, D.3
  • 46
    • 58149359842 scopus 로고    scopus 로고
    • Triple negative breast cancer: Risk factors to potential targets
    • Schneider B P, Weiner E P, Foulkes WD, et al. Triple negative breast cancer: Risk factors to potential targets. Clin Cancer Res 2008;14:8010-8
    • (2008) Clin Cancer Res , vol.14 , pp. 8010-8018
    • Schneider, B.P.1    Weiner, E.P.2    Foulkes, W.D.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.